logo
episode-header-image
Nov 2023
41m 10s

Obesity Drugs Enjoy a Much-Needed Winnin...

bloomberg
About this episode

Bloomberg Opinion Pharma Columnist Lisa Jarvis and Bloomberg News Health Reporter Madison Muller discuss a how a clinical trial in obesity drugs is punctuating a string of positive developments that could make the treatments more widely accessible. Kate Hao, Founder and CEO of Happy Mango, talks about helping immigrants secure loans for cars, homes and businesses. Bloomberg Businessweek Editor Joel Weber and Bloomberg News Senior Economics Writer Shawn Donnan provide the details of Shawn's Businessweek story Biden and Xi Meet at APEC to Navigate Rivalry and Economic Ties. And we Drive to the Close with David Dietze, Senior Portfolio Strategist at Peapack Private Wealth Management.
Hosts: Carol Massar and Tim Stenovec. Producer: Paul Brennan. 

See omnystudio.com/listener for privacy information.

Up next
Today
Inside Trump's Months-Long Effort to Get His Signature on US Currency
Newly-released documents offer a glimpse into the months-long effort to put a sitting president’s signature on US currency for the first time and the resulting tension inside the Bureau of Engraving and Printing. Bloomberg News Senior Investigative Reporter & FOIA Files newslette ... Show More
12m 14s
Aug 22
Bloomberg Businessweek Weekend: August 21st, 2026
Featuring some of our favorite conversations of the week from our daily radio show "Bloomberg Businessweek Daily." Hosted by Carol Massar and Tim StenovecHear the show live at 2PM ET on WBBR 1130 AM New York, Bloomberg 92.9 FM Boston, WDCH 99.1 FM in Washington D.C. Metro, Sirius ... Show More
38m 55s
Aug 21
Treasury Whiplash Leaves Traders Guessing Scott Bessent's Next Move
The people, companies and trends shaping the global economy. Watch Carol and Tim LIVE every day on YouTube: http://bit.ly/3vTiACF After a turbulent stretch for the US bond market, traders are heading into the weekend with questions about what Treasury Secretary Scott Bessent’s ne ... Show More
35m 53s
Recommended Episodes
Apr 2023
Those New Obesity Drugs Really Work–If You Can Afford Them
Pharmaceutical companies and insurance providers are at odds over a new class of drugs that have proven quite effective at helping people living with obesity lose weight. Bloomberg’s Robert Langreth and Emma Court join this episode to share their reporting on recent advancements ... Show More
25m 18s
Oct 2024
Hot shot: the wider promise of weight-loss jabs
<p>First they treated diabetes. Then obesity. Now <a href="https://www.economist.com/leaders/2024/10/24/its-not-just-obesity-drugs-like-ozempic-will-change-the-world?utm_campaign=a.io&utm_medium=audio.podcast.np&utm_source=theintelligence&utm_content=discovery.content.anonymous.t ... Show More
23m 58s
Aug 2024
Market Rally Aims for “Cloud Nine,” Bronfman's Paramount Bid, Eli Lilly CEO on Weight-Loss Drug 8/20/24
<p>Carl Quintanilla and Jim Cramer led off the show by delving into the broadening market rally, as the S&P 500 and Nasdaq aim for a ninth consecutive day of gains. David Faber called into the show with reporting on Edgar Bronfman's bid to acquire Paramount Global. Eli Lilly CEO ... Show More
44m 46s
Dec 2024
068 | The weight is over: How GLP-1 treatments are reshaping pharma and beyond
Weight-loss drugs have become a golden formula for pharma growth. In this episode we speak to Sector Advisor Maria Latorre and Senior Economist Michaela Grimm about how GLP-1 treatments like Ozempic and Wegovy are reshaping the industry, and the risks that lie ahead. SHOWNOTES: • ... Show More
11m 16s
Aug 2024
AI-Powered Weapons Startup Raises $1.5B & Mounjaro Soars Past Wegovy
Episode 384: Neal and Toby chat about the round of funding for a startup that could transform the landscape of warfare by combining tech and military manufacturing. Then, upheaval in Bangladesh has global economies nervous about its impacts, especially in the fashion industry. Ne ... Show More
28m 8s
Jan 2024
JP Morgan Healthcare Conference Highlights
Weight loss drugs are taking center spotlight, but other developing treatments could change how we live. Deidre Woollard caught up with Motley Fool biotech analyst Karl Thiel to discuss: - Biogen’s next shot at an Alzheimer’s treatment. - Why companies can’t “muscle their way” i ... Show More
26m 16s
Jul 2018
Amazon’s Health Care Threat Just Became A Reality: Ovide, Nisen
Bloomberg Opinion’s Max Nisen, health care columnist, and Shira Ovide, technology columnist, on Amazon buying Pillback.Chris Whalen, Chairman of Whalen Global Advisors, on bank stocks continued losing streak, and the privatization of Fannie and Freddie. Leland Miler, CEO of China ... Show More
30m 26s
Jun 2025
Meta Tries to Poach OpenAI Staff, David Sacks Weighs In On Genius Act
Bloomberg’s Caroline Hyde and Ed Ludlow discuss the impact of the stablecoin legislation that passed the Senate with White House AI and Crypto Czar David Sacks. Plus, Klarna CEO Sebastian Siemiatkowski talks about the startup's super-app ambitions; Zoox CEO Aicha Evans joins from ... Show More
45m 12s